Verastem, INC 8-K filings

NASDAQ

29 Jan 2024

VSTM

8-K: Verastem Oncology Outlines 2024 Strategic Priorities, Anticipates Key Data Readouts and Regulatory Submissions

Verastem Oncology is set to begin a rolling submission for FDA approval of its avutometinib and defactinib combination for recurrent low-grade serous ovarian cancer in the first half of 2024, among other key milestones.

NASDAQ

19 Jan 2024

VSTM

Verastem, INC

8-K: Verastem Stockholders Approve Option Exchange at Special Meeting

Verastem, Inc. stockholders approved a one-time exchange of certain stock options for new options at a special meeting held on January 17, 2024.